Promising combo for rare leukemia stalls: trial ends early
NCT ID NCT05464836
First seen Jan 09, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This study tested whether combining two drugs, CB-103 and venetoclax, could help control T-cell acute lymphoblastic leukemia (T-ALL) in teens and young adults whose cancer had come back or stopped responding to treatment. Only 2 people enrolled before the trial was stopped early. The goal was to see how many patients responded, but results are limited due to early termination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.